Use of recombinant activated factor VII in patients with Glanzmann's thrombasthenia: A review of the literature

Haemophilia

Volumn 20, Issue 4, 2014, Pages 464-471

  Rajpurkar, M ^a,b   Chitlur, M ^a   Recht, M ^c   Cooper, D L ^d  

^a CHILDREN'S HOSPITAL OF MICHIGAN   (United States)

^b WAYNE STATE UNIVERSITY   (United States)

^c OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^d NOVO NORDISK INC   (United States)

Author keywords

Bleeding; Glanzmann's thrombasthenia; rFVIIa

Indexed keywords

AMINOCAPROIC ACID; ANTIFIBRINOLYTIC AGENT; BLOOD CLOTTING FACTOR 8 PLUS VON WILLEBRAND FACTOR; DESMOPRESSIN ACETATE; HEMOSTATIC AGENT; RECOMBINANT BLOOD CLOTTING FACTOR 7A; TRANEXAMIC ACID; ANTIBODY; BLOOD CLOTTING FACTOR 7A; RECOMBINANT FVIIA; RECOMBINANT PROTEIN;

BLEEDING; CONTINUOUS INFUSION; DOSE RESPONSE; DRUG EFFICACY; DRUG SAFETY; EPISTAXIS; GASTROINTESTINAL HEMORRHAGE; GLANZMANN DISEASE; HUMAN; JUGULAR VEIN; OPEN STUDY; PRIORITY JOURNAL; REVIEW; SURGICAL TECHNIQUE; THROMBOEMBOLISM; TREATMENT RESPONSE; IMMUNOLOGY; SAFETY; THROMBASTHENIA; TREATMENT FAILURE;

ANTIBODIES; FACTOR VIIA; HUMANS; RECOMBINANT PROTEINS; SAFETY; THROMBASTHENIA; TREATMENT FAILURE;

EID: 84904666888     PISSN: 13518216     EISSN: 13652516     Source Type: Journal    
DOI: 10.1111/hae.12473     Document Type: Review

References (56)

1. George JN, Caen JP, Nurden AT. Glanzmann's thrombasthenia: the spectrum of clinical disease. Blood 1990; 75: 1383-95.
2. Spiess BD. Platelet transfusions: the science behind safety, risks and appropriate applications. Best Pract Res Clin Anaesthesiol 2010; 24: 65-83.
3. NovoSeven RT Coagulation Factor VIIa (Recombinant) Room Temperature Stable [prescribing information]. Novo Nordisk, Plainsboro, NJ; August, 2010.
4. NovoSeven [Summary of Product Characteristics]. Novo Nordisk A/S, Bagsværd, Denmark. July 2013.
5. Lisman T, Moschatsis S, Adelmeijer J, Nieuwenhuis HK, De Groot PG. Recombinant factor VIIa enhances deposition of platelets with congenital or acquired alpha IIb beta 3 deficiency to endothelial cell matrix and collagen under conditions of flow via tissue factor-independent thrombin generation. Blood 2003; 101: 1864-70.
6. Poon MC. Clinical use of recombinant human activated factor VII (rFVIIa) in the prevention and treatment of bleeding episodes in patients with Glanzmann's thrombasthenia. Vasc Health Risk Managt 2007; 3: 655-64.
7. Lisman T, Adelmeijer J, Heijnen HF, de Groot PG. Recombinant factor VIIa restores aggregation of alphaIIbbeta3-deficient platelets via tissue factor-independent fibrin generation. Blood 2004; 103: 1720-7.
8. Poon MC, D'Oiron R, Von Depka M, Khair K, Negrier C, Karafoulidou A et al. Prophylactic and therapeutic recombinant factor VIIa administration to patients with Glanzmann's thrombasthenia: results of an international survey. J Thromb Haemost 2004; 2: 1096-103.
9. Lak M, Scharling B, Blemings A, Sharifian R, Maleki Z, Daraee A et al. Evaluation of rFVIIa (NovoSeven) in Glanzmann patients with thromboelastogram. Haemophilia 2008; 14: 103-10.
10. Almeida AM, Khair K, Hann I, Liesner R. The use of recombinant factor VIIa in children with inherited platelet function disorders. Br J Haematol 2003; 121: 477-81.
11. Devecioglu O, Unuvar A, Anak S, Bilge I, Ander H, Ziylan O. Pyelolithotomy in a patient with Glanzmann thrombasthenia and antiglycoprotein IIb/IIIa antibodies: the shortest possible duration of treatment with recombinant activated factor VII and platelet transfusions. Turk J Pediatr 2003; 45: 64-6.
12. d'Oiron R, Menart C, Trzeciak MC, Nurden P, Fressinaud E, Dreyfus M et al. Use of recombinant factor VIIa in 3 patients with inherited type I Glanzmann's thrombasthenia undergoing invasive procedures. Thromb Haemost 2000; 83: 644-7.
13. Poon MC, Demers C, Jobin F, Wu JW. Recombinant factor VIIa is effective for bleeding and surgery in patients with Glanzmann thrombasthenia. Blood 1999; 94: 3951-3.
14. Tengborn L, Petruson B. A patient with Glanzmann thrombasthenia and epistaxis successfully treated with recombinant factor VIIa. Thromb Haemost 1996; 75: 981-2.
15. Ancliff P, Liesner R, Khair K, Hann I. The use of recombinant factor VIIa in a patient with severe Glanzmann's thrombasthenia to facilitate insertion of a Port-a-Cath. Blood Coagul Fibrinolysis 1999; 10: 447-8.
16. Browning L, Dogra S, Bourbonnais J. The Use of Recombinant Factor VIIa Use in a Patient with Glanzmann's Thrombasthenia and Diffuse Alveolar Hemorrhage. Poster Presentation at Congress of Society of Critical Care Medicine, 2011.
17. Ameri A, Stolte S. Correlation of activated clotting time (ACT) with rFVLLa infusion and clinical efficacy in a patient with Glanzmann thrombasthenia and platelet alloantibodies. Thromb Haemost 2002; 87: 1084.
18. Anwer A, Hanley J, Kumarendran K. Proposed management of pregnancy and labour in an inherited platelet disorder. Glanzmann's thrombasthenia. J Obstet Gynaecol 2007; 27: 421-3.
19. Bakdash S, Lyons JM, Bastacky SI, Pezzone MA, McGee JB, Schoen RE et al. Management of persistent gastric bleeding in a patient with Glanzmann's thrombasthenia. Am J Hematol 2008; 83: 411-15.
20. Balci YI, Karabulut A, Kabukcu S, Sari I, Keskin A. Intensive menstrual bleeding successfully treated with recombinant factor VIIa in Glanzmann thrombasthenia. Clin Appl Thromb Hemost 2011; 17: 320-2.
21. Bhat S, Yadav SP, Anjan M, Dinand V, Sachdeva A. Recombinant activated factor VII usage in life threatening hemorrhage: a pediatric experience. Indian J Pediatr 2011; 78: 961-8.
22. Buyukasik Y, Boyraz G, Selcuk I, Bektas O, Selcuk Tuncer Z. Giant abdominopelvic haematoma arising from ovulation in a Glanzmann's thrombasthenia patient with platelet refractoriness: treatment with surgery and intra-abdominal tranexamic acid. Acta Haematol 2012; 128: 154-7.
23. Caglar K, Cetinkaya A, Aytac S, Gumruk F, Gurgey A. Use of recombinant factor VIIa for bleeding in children with Glanzmann thrombasthenia. Pediatr Hematol Oncol 2003; 20: 435-8.
24. Chuansumrit A, Sangkapreecha C, Hathirat P. Successful epistaxis control in a patient with Glanzmann thrombasthenia by increased bolus injection dose of recombinant factor VIIa. Thromb Haemost 1999; 82: 1778.
25. Duman EN, Saylan S, Cekic B. Perioperative management of a pediatric patient with Glanzmann's thrombasthenia during adenoidectomy. Rev Bras Anestesiol 2012; 62: 548-53.
26. Erduran E, Aksoy A, Zaman D. The use of recombinant FVIIa in a patient with Glanzmann thrombasthenia with uncontrolled bleeding after tonsillectomy. Blood Coagul Fibrinolysis 2009; 20: 215-17.
27. Flood VH, Johnson FL, Boshkov LK, Thomas GA, Nugent DJ, Bakke AC et al. Sustained engraftment post bone marrow transplant despite anti-platelet antibodies in Glanzmann thrombasthenia. Pediatr Blood Cancer 2005; 45: 971-5.
28. Forde K, Mason C, Mathias M. Prolonged bleeding after exfoliation of a deciduous tooth in a patient with Glanzmann's thrombasthenia. Haemophilia 2012; 18: e58-9.
29. Humphreys I, Saraiya S, Belenky W, Dworkin J. Nasal packing with strips of cured pork as treatment for uncontrollable epistaxis in a patient with Glanzmann thrombasthenia. Ann Otol Rhinol Laryngol 2011; 120: 732-6.
30. Javed A, Ayyub M, Abrar S, Mansoor M, Khan B, Hussain T. Control of severe bleeding episode in case of Glanzmann's thrombasthenia refractory to platelet transfusion therapy by administering recombinant factor VIIa. J Ayub Med Coll Abbottabad 2009; 21: 171-3.
31. Kale A, Bayhan G, Yalinkaya A, Yayla M. The use of recombinant factor VIla in a primigravida with Glanzmann's thrombasthenia during delivery. J Perinat Med 2004; 32: 456-8.
32. Kaleelrahman M, Minford A, Parapia LA. Use of recombinant factor VIIa in inherited platelet disorders. Br J Haematol 2004; 125: 95-6.
33. Krishnamoorthy S, Kumar S, Kekre N. Hematuria: an uncommon presentation of Glanzmann's thrombasthenia-lessons learnt. Indian J Urol 2010; 26: 115-17.
34. Leticee N, Kaplan C, Lemery D. Pregnancy in mother with Glanzmann's thrombasthenia and isoantibody against GPIIb-IIIa: is there a foetal risk? Eur J Obstet Gynecol Reprod Biol 2005; 121: 139-42.
35. Phillips R, Richards M. Venous thrombosis in Glanzmann's thrombasthenia. Haemophilia 2007; 13: 758-9.
36. Uzunlar HI, Eroglu A, Senel AC, Bostan H, Erciyes N. A patient with Glanzmann's thrombasthenia for emergent abdominal surgery. Anesth Analg 2004; 99: 1258-60, table of contents.
37. Valentino LA. Use of rFVIIa in 4 children with Glanzmann thrombasthenia. J Pediatr Hematol Oncol 2006; 28: 653-8.
38. Vigren P, Strom JO, Petrini P, Callander M, Theodorsson A. Treatment of spontaneous intracerebral haemorrhage in Glanzmann's thrombasthenia. Haemophilia 2012; 18: e381-3.
39. Zinke RA, Ornstein DL, Holmes CE. Factor VIII/von Willebrand factor concentrate for treatment of life threatening epistaxis in Glanzmann's thrombasthenia. Haemophilia 2010; 16: 701-4.
40. Andre JM, Galambrun C, Trzeciak MC, Dargaud Y, Kaplan-Gouet C, Jallu V et al. Acquired Glanzmann's thrombasthenia associated with acute lymphoblastic leukemia. J Pediatr Hematol Oncol 2005; 27: 554-7.
41. Bay A, Oner AF. Glanzmann thrombasthenia successfully operated for nasal deformation with recombinant factor VIIA. Indian Pediatr 2006; 43: 1094.
42. Chuansumrit A, Suwannuraks M, Sri-Udomporn N, Pongtanakul B, Worapongpaiboon S. Recombinant activated factor VII combined with local measures in preventing bleeding from invasive dental procedures in patients with Glanzmann thrombasthenia. Blood Coagul Fibrinolysis 2003; 14: 187-90.
43. Dargaud Y, Bordet JC, Trzeciak MC, Vinciguerra C, Negrier C. A case of Glanzmann's thrombasthenia successfully treated with recombinant factor viia during a surgical procedure: observations on the monitoring and the mechanism of action of this drug. Haematologica 2006; 91: ECR20.
44. Depner C, Schmid R, Kirchhoff P, Oertli D. Perioperative management of Glanzmann's syndrome: how we did it!. Blood Coagul Fibrinolysis 2010; 21: 283-4.
45. Domschke C, Strowitzki T, Huth-Kuehne A, Staritz P, Sohn C, Schuetz F. Successful in vitro fertilization and pregnancy in Glanzmann thrombasthenia. Haemophilia 2012; 18: e380-1.
46. Goksu S, Gul R, Ozen O, Yilmaz M, Buyukbebeci O, Oner U. Intravenous regional analgesia in a patient with Glanzmann thrombastenia. Middle East J Anesthesiol 2010; 20: 589-91.
47. Gunaydin B, Ozkose Z, Pezek S. Recombinant activated factor VII and epsilon aminocaproic acid treatment of a patient with Glanzmann's thrombasthenia for nasal polipectomy. J Anesth 2007; 21: 106-7.
48. Ismael F, van der Meer J, de Wolf JT, Kuizenga K, Aarts LP, Hendriks HG. Thromboelastographic evaluation of recombinant factor VIIa in a child with Glanzmann's thrombasthenia. Anesth Analg 2006; 103: 791-2.
49. Kashiwagi H, Kiyomizu K, Kamae T, Nakazawa T, Tadokoro S, Takiguchi S et al. Molecular analysis of a patient with type I Glanzmann thrombasthenia and clinical impact of the presence of anti-alphaIIbbeta3 alloantibodies. Int J Hematol 2011; 93: 106-11.
50. Lison S, Spannagl M, Heindl B. Perioperative haemostatic management of Glanzmann thrombasthenia for abdominal surgery. Blood Coagul Fibrinolysis 2009; 20: 371-3.
51. Lombardo VT, Sottilotta G. Recombinant activated factor VII combined with desmopressin in preventing bleeding from dental extraction in a patient with Glanzmann's thrombasthenia. Clin Appl Thromb Hemost 2006; 12: 115-16.
52. Monte S, Lyons G. Peripartum management of a patient with Glanzmann's thrombasthenia using Thrombelastograph. Br J Anaesth 2002; 88: 734-8.
53. Wertz D, Boveroux P, Peters P, Lenelle J, Franssen C. Surgical resection of a sphenoid wing meningioma in a patient with Glanzmann thrombasthenia. Acta Anaesthesiol Belg 2011; 62: 83-6.
54. Yilmaz BT, Alioglu B, Ozyurek E, Akay HT, Mercan S, Ozbek N. Successful use of recombinant factor VIIa (NovoSeven) during cardiac surgery in a pediatric patient with Glanzmann thrombasthenia. Pediatr Cardiol 2005; 26: 843-5.
55. van Buuren HR, Wielenga JJ. Successful surgery using recombinant factor VIIa for recurrent, idiopathic nonulcer duodenal bleeding in a patient with Glanzmann's thrombasthenia. Dig Dis Sci 2002; 47: 2134-6.
56. Abshire T, Kenet G. Safety update on the use of recombinant factor VIIa and the treatment of congenital and acquired deficiency of factor VIII or IX with inhibitors. Haemophilia 2008; 14: 898-902.